Scala Biodesign Raises $5.5 Million in Seed Round

by Kay Aloha Villamor in September 12th, 2023

Scala Biodesign, a Tel Aviv, Israel-based startup that aims to provide a one-stop shop for efficient and economical protein engineering, has emerged from stealth with $5.5 million in seed funding.

SaaS Investors

TLV Partners led the round.

Founded in 2015, TLV Partners is an Israeli VC firm investing in early-stage startups and partnering with innovative entrepreneurs to build category-defining companies. The firm prefers to invest in artificial intelligence, cloud tech, data, cybersecurity, dev tools, e-commerce, fintech, health, property tech, and quantum sector firms based in Israel.

Scala Biodesign Use of Funds

The funds will be used to accelerate and improve the development of proteins for biotechnology applications.

About Scala Biodesign

Founded in 2022 by Dr. Ravit Netzer and Dr. Adi Goldenzweig, Scala Biodesign provides a unique one-shot computational solution to accelerate the development of proteins into commercial products. Its technology combines evolutionary analysis, atomistic protein design calculations, and AI to design proteins with superior properties, which can be used in the pharmaceutical, chemical, and sustainability industries to develop commercial products faster and more effectively.

Funding Details

Company: Scala Biodesign

Raised: $5.5M

Round: Seed Round

Funding Month: September 2023

Lead Investors: TLV Partners 

Additional Investors:

Company Website: 

Software Category: One-shot Computational Solution

Source: Ronny Hassid 

Your cart